You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

~ Buy the RYDAPT (midostaurin) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR RYDAPT

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for RYDAPT

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01830361 ↗	Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML	Completed	Novartis Pharmaceuticals	Phase 2	2013-03-13	To assess the efficacy of tyrosine-kinase inhibitor midostaurin in c-KIT or FLT3-ITD mutated t(8;21) AML. To assess the efficacy of midostaurin depending on the type of c-KIT mutation
NCT01830361 ↗	Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML	Completed	Technische Universität Dresden	Phase 2	2013-03-13	To assess the efficacy of tyrosine-kinase inhibitor midostaurin in c-KIT or FLT3-ITD mutated t(8;21) AML. To assess the efficacy of midostaurin depending on the type of c-KIT mutation
NCT02115295 ↗	Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia	Recruiting	National Cancer Institute (NCI)	Phase 2	2014-05-19	This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for RYDAPT

Condition Name

Chart
Table

Condition Name for RYDAPT
Intervention	Trials
Acute Myeloid Leukemia	10
Myelodysplastic Syndrome	2
Myelodysplastic Syndrome With Excess Blasts-2	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for RYDAPT
Intervention	Trials
Leukemia, Myeloid, Acute	11
Leukemia, Myeloid	11
Leukemia	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for RYDAPT

Trials by Country

Map
Table

Trials by Country for RYDAPT
Location	Trials
United States	82
Germany	5
Netherlands	2
Switzerland	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for RYDAPT
Location	Trials
California	4
Florida	4
Washington	3
Tennessee	3
North Carolina	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for RYDAPT

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for RYDAPT
Clinical Trial Phase	Trials
Phase 3	1
Phase 2/Phase 3	1
Phase 2	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for RYDAPT
Clinical Trial Phase	Trials
Recruiting	5
Active, not recruiting	2
Withdrawn	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for RYDAPT

Sponsor Name

Chart
Table

Sponsor Name for RYDAPT
Sponsor	Trials
Novartis Pharmaceuticals	3
National Cancer Institute (NCI)	3
Pfizer	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for RYDAPT
Sponsor	Trials
Other	14
Industry	9
NIH	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.